AND ASA (CH. 40) EXAM QUESTIONS
AND ANSWERS GRADED A+ 2025/2026
Inhibition of synthesis of prostaglandins - ANS action of NSAIDs
cox-1 - ANS produces prostanoids for gastric cytoprotection, vascular homeostasis, platelet
aggregation, and reproductive and kidney fx
cox-2 - ANS elevated production of prostanoids that occurs in sites of chronic dz and
inflammation
Cox-2, accting for anti-inflammatory effects - ANS glucocorticoids inhibit
modulating pain, inflammation, and fever; control acid secretion/mucus production in GI,
uterine contractions, and renal BF; mediators in allergic and inflammatory processes -
ANS therapeutic uses of prostaglandins
alprostadil; PGE - ANS maintains patency of ductus arteriosus
congential heart conditions and erectile dysfx - ANS indications for alprostadil
chronic idiopathic constipaiton, opioid-induced constipation, IBS w/ constipation -
ANS lubiprostone indications
1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
, increasing intestinal fluid secretion - ANS action of lubiprostone
nausea and diarrhea; take w/ food to decrease nausea - ANS a/es of lubiprostone
miso - ANS protect mucosal lining of stomach during chronic NSAID treatment
miso - ANS reduces gastric acid secretion and stimulates mucus and bicarb produciton
NSAID related ulcers - ANS miso decreases incidence of
diclofenac and miso - ANS combo of NSAID w/ miso
labor induction, abortion - ANS why is miso contraindicated in pregnancy?
diarrhea, ab pain - ANS a/es of miso
dinoprosotone - ANS cervical ripening and abortion agent
fever, chills, nausea, diarrhea, HA - ANS a/es of dinoprostone
open-angle glaucoma; increases outlfow and decrease IOP - ANS bimatoprost, latanoprost,
tafluprost, and travoprost treat what
bimatoprost - ANS increases eyelash prominence, length, darkness (eyelash hypotrichosis)
blurred vision, iris color change (increased brown pigmentation), increased number and
pigment of eyelashes, ocular irritation, foreign body sensation - ANS a/es of bimatoprost,
latanoprost, tafluprost, and travoprost
2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.